Redeye keeps its Base Case and forecasts unchanged.
TCECUR Sweden AB (”TCECUR” eller ”Koncernen”) meddelade den 24 september år 2024 att Jacob Philipsso...
Q3 report due 24 October, we evaluate D2C potential We forecast net sales of SEK 186m, EBITA of SEK ...
Q3 report due 25 October We forecast SEK 551m net sales, SEK 83m EBITA We reiterate fair value range...
Aptahem har gjort stora framsteg med läkemedelskandidaten Apta-1 för behandling av svåra inflammator...
Redeye comments on Arise’s divestment of a 40MW battery project for a total consideration of SEK30m ...
Cibus, which raised EUR ~82m new equity two weeks ago to fund growth, announced after market close o...
Redeye leaves a brief comment on today's news that Genovis' has launched the second generation of it...
Redeye comments on Active Biotech’s rights issue of SEK35m with a subscription price of SEK 0.
Redeye leaves a comment following Alzinova’s announcement of the appointment of Tord Labuda as the n...
Redeye initiates coverage of Cinclus Pharma, a Swedish biotech company offering a next-generation so...
Vi inleder bevakning på Premium Snacks Nordic AB, ett svenskt bolag som utvecklar, tillverkar och sä...
Redeye endorses that the FDA has provided positive guidance regarding generic substitutability for I...
Redeye provides a brief comment on the expansion of the Digital Extremes development agreement, whic...
Redeye positively reviews the Thermo Fisher deal’s potential and the company’s US sales outlook.
Presented a clear and detailed operating blueprint SEK 3.
Mangold uppdaterar sin syn på mobiloperatören My Beat efter det första kvartalet.
Redeye initiates coverage of Dala Energi, a group consisting of four business segments and five asso...
Redeye comments on EveryMatrix’s cash offer to acquire Fantasma Games at a price of SEK59 per share,...
Redeye provides a longer note following WntResearch’s failed phase 2 study and CEO interview.
